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818-4 etarminants of Coronary Collateral Vessels Formation 
Edmund O. Ana. Duana Walton, Kristy Breuhl, Marin Schweizer, Timothy D. Henry, 
Hennepin County Medical Center, Minneapolis, Minnesota, University of Minnesota, 
Minneapolis, Minnesota. 
BACKGROUND: Patients with coronary collateral vessels have less myocardial ischemia 
and better outcome post myocardial infarction (MI) than patients without collaterals. How- 
ever, there is limited information on the determinants of collateral vessels formation. We 
evaluated the effect of clinical, angiographic, laboratory parameters and medications on 
a cohort of patients undergoing coronary angiography. 
METHODS: 300 consecutive patients undergoing coronary angiography were evaluated. 
188 patients had coronary stenosis >75% (historically defined as sufficient for the devel- 
opment of coronary collateral circulation) were included in the analysis. Collateral vessel 
circulation was graded according to Rentrop classification and the collateral score was 
calculated by summing the Rentrop numbers of every patient. 
RESULTS: The mean age was 58.5±11 years & 64% were male. 44% had diabetes and 
49% had previous MI. 
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Predictors Yes No P value 
Previous myocardial infarction 1.21_+1.08 0.94_+1.04 0.01 
Previous revascularization procedure 0.72±1 1.40±1.07 <0.001 
Unstable lesion 0.94±1.04 1.26+1.13 0.01 
Diabetes mellitus 0.98_+0.97 1.17±1.18 0.25 
>70 years old 1.01-+1.09 1.10±1.91 0.53 
Lipid lowering agent 0.92-+1.05 1.24_+1.10 0.008 
Aspirin 1.14-+1.08 0.81±1.11 0.01 
CONCLUSIONS: Collateral vessels was more apparent in patients with previous MI and 
patients on aspirin. In contrast, patients with unstable presentation, previous revascular- 
ization and those on lipid lowering agent had lower Rentrop scores. Diabetes and age 
were not predictive. In addition, collateral development was more frequent in patients 
with occluded or subtotal lesions. Development of coronary collateral vessels is a com- 
plex process and the determinants in an individual patient require further study as we 
investigate new therapeutic options to stimulate coronary angiogenesis. 
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818-5 Prognostic Impacts of Practical Assessment for 
Mlcrovaecular Coronary Vasomotor Dysfunction 
Tatsuaki Murokami. Kazuo Ohseto, Fukui Cardiovascular Center, Fukui, Japan. 
Background. Although microvascular coronary vasomotor dysfunction (VMD) is thought 
to contribute to coronary atherothrombosis, there has been little practical evidence for 
the relationship. This study investigated whether practically evaluated VMD has prognos- 
tic impacts. 
Methods. VMD was graded by 2 variables: (1) the endothelium-independent flow 
increases to infusion of ATP (50p_g) (FN), and (2) the endothelium-depondent increases 
to infusion of acetylcholine (50~g) (FE) into the normal or minimally diseased (%-diame- 
tar stenosis <30%) left coronary artery using quantitative coronary arteriography and 
doppler-wire in consecutive 150 patients with suspected coronary artery disease, The 
patients were categorized into tertile groups according to the values of FN and FE, and 
we prospectively followed-up their major adverse coronary events (MACE: cardiac death, 
CABG, heart failure, non-fatal acute coronary syndrome). 
Results. For a mean follow-up period of 64 months (range; 58 to 81) with 100% follow- 
up, the patients in the lower third with severe VMD (Group-L) of 2 variables more fre- 
quently developed MACE (Group-L versus Group-M with mild VMD plus Group-H with 
normal vasomotor function, by Kaplan-Meier analysis). All patients with MACE belonged 
to Group-L of FN or FE. Cox proportional nalysis showed severe VMD of FN or FE was 
an independent predictor for MACE. 
Conclusion. These results suggest evaluation of microvascular coronary vasomotor 
function hi~]hly predicts future coronary events. 
Group-L Group-M Group-H 
FN 12 (24%) 3 (S%) 3 (6%) 
FE 14 (28%) 3 (6%) 1 (2%) 
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821-1 Potent Cardiac Unloading Actions of a New Synthetic 
NatriureUc Peptide (BD-NP) in Experimental Severe 
Congestive Heart Failure 
Guido Boerrioter, Lisa C. Costallo, Ondrej Lisy, Alessandro Cataliotti, Toshihiro Tsuruda, 
Gall J, Harry, John C. Burnett, Jr., Mayo Clinic and Foundation, Rochester, Minnesota. 
Background: Natduretic peptides (NPs) play an important role in cardiorenal homeosta- 
sis. BNP has been approved for the treatment of acute heart failure. DNP was first identi- 
fied in the green mamba snake and due to its long C-terminus may be more resistant o 
enzymatic degradation by neutral endopeptidase. We designed and synthesized a new 
NP by combining the ring structure and N-terminus of BNP with the extended C-terminus 
of DNP. We assessed the cardiorenal actions of this chimeric BD-NP in a model of 
severe congestive heart failure (CHF). 
Methods: Severe CHF was induced in 7 dogs by rapid ventricular pacing (240 bpm) for 
10 days. Cardiorenal parameters were assessed in 30-minute clearances at baseline, 
with low dose (10 ng/kg/min) and high dose (50 ngrkg/min) BD-NP infusion, and after a 
washout period of 30 minutes (post infusion). Values are expressed as maan±SEM; 
*p<0.05 vs. Baseline. 
Results: Administration of low and high dose BD-NP decreased right atrial pressure 
(from baseline 3.3±2.2 to 2.0+_2.1" and -0.1:~?..1" mm Hg), pulmonary artery pressure 
(from 22±3 to 19±3" and 16+3" mm Hg), and pulmonary capillary wedge pressure (15+3 
to 12+3" and 10_+3* mm Hg). Mean arterial pressure, cardiac output, and systemic vascu- 
lar resistance remained unchanged. Urine flow (from 0.22±0.09 to 0.49±0.13 and 
1.07±0.16" mLJmin) and urinary sodium excretion (26±14 to 70+20 and 195±29" liEq/ 
min) increased. Renal blood flow (from 47±5 to 54±5 and 64-+6* mL/min) and glomerular 
filtration rate (GFR) (from 27+5 to 35±7 and 57i-9" mL/min) increased. Plasma cGMP 
(from 19+~?. to 28±2* and 39±4* pmol/mL) and urinary cGMP excretion (from 1742±296 to 
3472-+583 and 9658-+3362* pmol/min) markedly increased, whereas plasma renin activity 
(from 6.6::2.2 to 4.8+1.8 and 3.2±1.4" ng/m!.Jh) and angiotensin II (from 81±29 to 24+10" 
and 10-]:3" pg/ml) decreased. These beneficial effects were sustained in the post infusion 
clearance. 
Conclusion: The new chimeric natriuretic peptide BD-NP decreases cardiac filling pros- 
sures, is diuretic and natriuretic, enhances GFR, and suppresses the renin-angiotensin 
system. Further studies are warranted to assess the therapeutic potential of this unique 
designer peptide in cardiorenal disease. 
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821-2 Renoprotactive Effect of Chronic Adrenomedullin 
Infusion in Dahl Salt-Sensitive Rats 
Toshio Nishikimi, Naihiko Kobayashi, Yosuke Mori, Kazuyoshi Tadokoro, Xing Wang, 
Kazumi Akimoto, Kenji Kangawa, Hiroaki Matsuoka, Dokkyo University School of 
Medicine Medicine, Mediocine, Mibu, Tochigi 321-0293, Japan, National Cardiovascular 
Center, Osaka, Japan. 
Background: Adrenomedullin (AM) is a potent vasodilatory and natriuretic peptide that 
plays an important role in pathophysiology of cardiovascular disease. Recent studies 
demonstrated that AM has inhibitory effect of proliferation and DNA synthesis in mesan- 
gial cells, vascular smooth muscle cells, and endothelial cells in vitro. However, whether 
administration ofAM has renoprotective effect in vivo remains unknown. 
This study was designed to examine whether chronic AM infusion has renoprotective 
effects in hypertensive rats. 
Methods: Human recombinant AM (500no/h) or vehicle was infused for approximately 7 
weeks by osmotic minipump in 11-week-old Dahl salt-sensitive rats (DS-AM, n=9; DS- 
coot, n=9 ), Dahl salt-resistant rats were used as a control (DR, n=9), After 7 weeks of 
treatment, blood pressure, renal function, histological findings, hormone levels, and renal 
molecular markers were measured. 
Results: DS-cont was characterized by decreased kidney function, impaired histological 
findings, altered hormone levels, and altered renal molecular markers. Chronic AM treat- 
ment significantly improved renal function (serum Cre: -87%, serum BUN: -73%, CCr: 
+114%, urinary protein excretion: -59%) without changing mean arterial pressure (-4%). 
Histological examination revealed that chronic AM infusion significantly improved glomer- 
ular injury score (-54%). Chronic AM treatment significantly inhibited increase of endoge- 
nous plasma rat AM levels (-97%), plasma renin concentration (-289%), aldosterone 
levels (-82%) and decreased tissue angiotensin II levels both in renal codex and 
medulla(-80%, -93%). Furthermore, AM infusion significantly decreased mRNA expres- 
sion of TGF-beta both in renal cortex and medulla (-63%, -115%), ACE both in renal cor- 
tex and medulta (-137%, -79%), renin both in renal cortex and medulla (-230%, -134%), 
and increased mRNA expression of ATl-receptor in renal codex (+46%), 
Conclusion: These results suggest hat chronic AM infusion has renoprotective effects in 
this type of hypertension model, at least in part, via inhibition of circulating and renal tis- 
sue renin-angiotensin system. 
